Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Annals of Oncology

Volumn 21, Issue , 2010, Pages vi1-vi10

  Van Cutsem, E ^a   Dicato, M ^b   Arber, N ^c   Berlin, J ^d   Cervantes, A ^e   Ciardiello, F ^f   De Gramont, A ^g   Diaz Rubio, E ^h   Ducreux, M ⁱ   Geva, R ^a,c   Glimelius, B ^j   Jones, R Glynne ^k   Grothey, A ^l   Gruenberger, T ^m   Haller, D ⁿ   Haustermans, K ^a   Labianca, R ^o   Lenz, H J ^p   Minsky, B ^q   Nordlinger, B ^r   Ohtsu, A ^s   Pavlidis, N ^t   Rougier, P ^r   Schmiegel, W ^u   Van de Velde, C ^v   Schmoll, H J ^w   Sobrero, A ^x   Tabernero, J ^y   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF VALENCIA   (Spain)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g HÔPITAL SAINT ANTOINE   (France)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UPPSALA UNIVERSITY   (Sweden)

^k MOUNT VERNON HOSPITAL   (United Kingdom)

^l MAYO CLINIC   (United States)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o OSPEDALI RIUNITI   (Italy)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^q UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^r HÔPITAL AMBROISE PARÉ   (France)

^s NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^t UNIVERSITY OF IOANNINA   (Greece)

^u RUHR UNIVERSITY BOCHUM   (Germany)

^v LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^w MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^x UNIVERSITY OF GENOA   (Italy)

^y HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

COLORECTAL TUMOR; CONFERENCE PAPER; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; METASTASIS; MICROSATELLITE INSTABILITY; MUTATION; PATHOLOGY; PROGNOSIS; SPAIN;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPAIN;

EID: 77956625930     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq273     Document Type: Conference Paper

References (98)

1. Jemal, A., Siegel, R., Ward, E., et al. Cancer statistics, 2008. CA Cancer J Clin 58:2 (2008), 71–96.
2. Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., Boyle, P., Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:3 (2007), 581–592.
3. Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:22 (2009), 3677–3683.
4. Seymour, M.T., Maughan, T.S., Ledermann, J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370:9582 (2007), 143–152.
5. Koopman, M., Antonini, N.F., Douma, J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:9582 (2007), 135–142.
6. Hecht, J.R., Mitchell, E., Chidiac, T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:5 (2009), 672–680.
7. Tol, J., Koopman, M., Cats, A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:6 (2009), 563–572.
8. Falcone, A., Ricci, S., Brunetti, I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:13 (2007), 1670–1676.
9. Souglakos, J., Androulakis, N., Syrigos, K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:6 (2006), 798–805.
10. Chun, Y.S., Vauthey, J.N., Boonsirikamchai, P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:21 (2009), 2338–2344.
11. Sargent, D.J., Conley, B.A., Allegra, C., Collette, L., Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:9 (2005), 2020–2027.
12. Tournigand, C., Andre, T., Achille, E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:2 (2004), 229–237.
13. Rougier, P., Van Cutsem, E., Bajetta, E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:9138 (1998), 1407–1412.
14. Kohne, C.H., Cunningham, D., Di, C.F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:2 (2002), 308–317.
15. Graf, W., Glimelius, B., Pahlman, L., Bergstrom, R., Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 27:9 (1991), 1119–1123.
16. Lavin, P., Mittelman, A., Douglass, H. Jr, Engstrom, P., Klaassen, D., Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report. Cancer 46:7 (1980), 1536–1543.
17. Kemeny, N., Braun, D.W. Jr, Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 74:5 (1983), 786–794.
18. Mitry, E., Douillard, J.Y., Van Cutsem, E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15:7 (2004), 1013–1017.
19. Sargent, D.J., Kohne, C.H., Sanoff, H.K., et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27:12 (2009), 1948–1955.
20. Papamichael, D., Audisio, R., Horiot, J.C., et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 20:1 (2009), 5–16.
21. Pallis, A.G., Papamichael, D., Audisio, R., et al. EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients. Cancer Treat Rev 36:1 (2010), 83–90.
22. Folprecht, G., Seymour, M.T., Saltz, L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:9 (2008), 1443–1451.
23. Scappaticci, F.A., Skillings, J.R., Holden, S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:16 (2007), 1232–1239.
24. Edler, D., Glimelius, B., Hallstrom, M., et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:7 (2002), 1721–1728.
25. AJCC Cancer Staging Manual7th edn. Springer 2010.
26. Smith, T.J., Hillner, B.E., Bear, H.D., Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?. J Natl Cancer Inst 95:10 (2003), 695–697.
27. Onega, T., Duell, E.J., Shi, X., Demidenko, E., Gottlieb, D., Goodman, D.C., Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev 66:5 (2009), 542–560.
28. Smith, T.J., Hillner, B.E., Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 19:11 (2001), 2886–2897.
29. Koukourakis, M.I., Giatromanolaki, A., Simopoulos, C., Polychronidis, A., Sivridis, E., Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22:1 (2005), 25–30.
30. Grem, J., The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 9:4 (1997), 380–387.
31. Vilar, E., Gruber, S.B., Microsatellite instability in colorectal cancer – the stable evidence. Nat Rev Clin Oncol 7:3 (2010), 153–162.
32. Gryfe, R., Kim, H., Hsieh, E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:2 (2000), 69–77.
33. Benatti, P., Gafa, R., Barana, D., et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11:23 (2005), 8332–8340.
34. Popat, S., Hubner, R., Houlston, R.S., Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:3 (2005), 609–618.
35. Ogino, S., Nosho, K., Kirkner, G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:1 (2009), 90–96.
36. Roth, A.D., Tejpar, S., Delorenzi, M., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:3 (2010), 466–474.
37. EVan CutsemILangGFolprechtCetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trialGastrointestinal Cancers SymposiumOrlando, 2010: 281.
38. Samowitz, W.S., Sweeney, C., Herrick, J., et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:14 (2005), 6063–6069.
39. Ogino, S., Meyerhardt, J.A., Irahara, N., et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:23 (2009), 7322–7329.
40. Rougier, P., Bugat, R., Douillard, J.Y., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:1 (1997), 251–260.
41. Saltz, L.B., Douillard, J.Y., Pirotta, N., et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:1 (2001), 81–91.
42. Steinberg, J., Erlichman, C., Gadalla, T., Fine, S., Wong, A., Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 28A:11 (1992), 1817–1820.
43. Giacchetti, S., Perpoint, B., Zidani, R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:1 (2000), 136–147.
44. Saltz, L.B., Cox, J.V., Blanke, C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:13 (2000), 905–914.
45. Freyer, G., Rougier, P., Bugat, R., et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 83:4 (2000), 431–437.
46. Strimpakos, A.S., Cunningham, D., Mikropoulos, C., Petkar, I., Barbachano, Y., Chau, I., The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 21:5 (2010), 1013–1019.
47. Sunga, A., Rajput, A., Yang, G.Y., et al. Carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer receiving systemic chemotherapy. J Clin Oncol, 23, 2005, 3615.
48. Ward, U., Primrose, J.N., Finan, P.J., et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67:5 (1993), 1132–1135.
49. Wang, W.S., Lin, J.K., Lin, T.C., et al. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Colorectal Dis 16:2 (2001), 96–101.
50. Iwanicki-Caron, I., Di Fiore, F., Roque, I., et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 26:22 (2008), 3681–3686.
51. Van Cutsem, E., Peeters, M., Siena, S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:13 (2007), 1658–1664.
52. Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
53. Moore, M.J., Goldstein, D., Hamm, J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:15 (2007), 1960–1966.
54. Van Cutsem, E., Humblet, Y., Gelderblom, H., et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. Gastrointestinal Cancers Symposium Orlando, 2007, 237.
55. Scartozzi, M., Galizia, E., Chiorrini, S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:2 (2009), 227–230.
56. Spano, J.P., Chodkiewicz, C., Maurel, J., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:9630 (2008), 2101–2108.
57. Mir, O., Ropert, S., Alexandre, J., Goldwasser, F., Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20:5 (2009), 967–970.
58. Poole, C., Gardiner, J., Twelves, C., et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:3 (2002), 225–234.
59. Cassidy, J., Twelves, C., Van Cutsem, E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:4 (2002), 566–575.
60. Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine. Nephron 16:1 (1976), 31–41.
61. Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G., McLeod, H.L., UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:17 (2007), 1290–1295.
62. Hoskins, J.M., McLeod, H.L., UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 27:15 (2009), 2419–2421.
63. Miya, T., Goya, T., Fujii, H., et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 19:1 (2001), 61–67.
64. Nalluri, S.R., Chu, D., Keresztes, R., Zhu, X., Wu, S., Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:19 (2008), 2277–2285.
65. Pereg, D., Lishner, M., Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?. Eur Heart J 29:19 (2008), 2325–2326.
66. Lievre, A., Bachet, J.B., Le Corre, D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:8 (2006), 3992–3995.
67. De Roock, W., Piessevaux, H., De Schutter, J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:3 (2008), 508–515.
68. Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:10 (2008), 1626–1634.
69. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:17 (2008), 1757–1765.
70. Ciardiello, F., Tortora, G., EGFR antagonists in cancer treatment. N Engl J Med 358:11 (2008), 1160–1174.
71. Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., Ciardiello, F., Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6:9 (2009), 519–527.
72. Artale, S., Sartore-Bianchi, A., Veronese, S.M., et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:25 (2008), 4217–4219.
73. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B., Velculescu, V.E., Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418(6901), 2002, 934.
74. Di Nicolantonio, F., Martini, M., Molinari, F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:35 (2008), 5705–5712.
75. Loupakis, F., Ruzzo, A., Cremolini, C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:4 (2009), 715–721.
76. Lambrechts, D., De Roock, W., Prenen, H., et al. The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol, 27, 2009, 9020.
77. Tejpar, S., De Roock, W., PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. Eur J Cancer, 7, 2009, 322.
78. Kohne, C., Rougier, P., Stroh, C., Schlichting, M., Bokemeyer, C., Van Cutsem, E., Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Gastrointestinal Cancers Symposium Orlando, 2010, 406.
79. Santini, D., Loupakis, F., Canestrari, E., et al. Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: Implications for treatment with anti-EGFR antibodies. Gastrointestinal Cancers Symposium Orlando, 2010, 349.
80. Jonker, D.J., Karapetis, C., Harbison, C., et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus best supportive care (BSC). J Clin Oncol, 27, 2009, 4016.
81. Jacobs, B., De Roock, W., Piessevaux, H., et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27:30 (2009), 5068–5074.
82. Linot, B., Capitain, O., Metges, J., et al. Gamelin. Impact of PI3K, BRAF, and KRAS mutations on efficacy intensified FOLFIRI + cetuximab regimen in advanced colorectal cancer Gastrointestinal Cancers Symposium Orlando. 2010, 365.
83. Frattini, M., Saletti, P., Romagnani, E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:8 (2007), 1139–1145.
84. Perrone, F., Lampis, A., Orsenigo, M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:1 (2009), 84–90.
85. Loupakis, F., Pollina, L., Stasi, I., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:16 (2009), 2622–2629.
86. Ruzzo, A., Graziano, F., Loupakis, F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:10 (2007), 1247–1254.
87. Liang, J., Jiang, T., Yao, R.Y., Liu, Z.M., Lv, H.Y., Qi, W.W., The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 2009 Dec 4 [Epub ahead of print].
88. Viguier, J., Boige, V., Miquel, C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:17 (2005), 6212–6217.
89. Kim, S.H., Kwon, H.C., Oh, S.Y., et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32:1 (2009), 38–43.
90. Shirota, Y., Stoehlmacher, J., Brabender, J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:23 (2001), 4298–4304.
91. Soong, R., Shah, N., Salto-Tellez, M., et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19:5 (2008), 915–919.
92. Martinez-Balibrea, E., Abad, A., Aranda, E., et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44:9 (2008), 1229–1237.
93. Findlay, M.P., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., Aherne, G.W., Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:6 (1997), 903–909.
94. Koopman, M., Venderbosch, S., van Tinteren, H., Ligtenberg, M.J., Nagtegaal, I., Van Krieken, J.H., et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 45:11 (2009), 1999–2006.
95. van Kuilenburg, A.B., Haasjes, J., Richel, D.J., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:12 (2000), 4705–4712.
96. van Kuilenburg, A.B., Muller, E.W., Haasjes, J., et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:5 (2001), 1149–1153.
97. Van Kuilenburg, A.B., Meinsma, R., Zoetekouw, L., Van Gennip, A.H., High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:7 (2002), 555–558.
98. Schmoll, H.J., Sargent, D., Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet 370 (2007), 105–107.